ViGenCell Inc.’s ‘VT-EBV-N’ Designated for Expedited Review by the Ministry of Food and Drug Safety… Seeking Conditional Approval
Eligible for Expedited Review and Tailored Review… Pursuing Domestic Approval and Technology Transfer in Parallel
Phase 2 Clinical Trial Shows 95% Disease-Free Survival Rate at 2 Years… 100% Overall Survival Rate at 4 Years
[Edaily Reporter KIM JI-WAN ] ViGenCell Inc.(308080)is expected to accelerate its efforts to secure domestic approval for “VT-EBV-N,” a treatment for NK/T-cell lymphoma currently under development. With the drug designated as an advanced biopharmaceutical eligible for expedited processing by the Ministry of Food and Drug Safety, the company has laid the groundwork to utilize priority review and other expedited procedures.
ViGenCell Inc. website. (Screenshot by ReporterKIM JI-WAN )
ViGenCell Inc. announced on the 17th that the designation of “VT-EBV-N” as an advanced biopharmaceutical eligible for expedited review—for which the company applied last June—was finalized this month. VT-EBV-N is an EBV-antigen-specific T-cell therapy being developed to treat EBV-positive extranodal NK/T-cell lymphoma, a rare blood cancer with a high risk of recurrence.
The designation for expedited review is a system designed to support the development and review of treatments for severe or rare life-threatening diseases for which there are no alternative therapies. Designated products receive tailored reviews and priority review from a dedicated review team and are eligible to apply for conditional marketing authorization.
Based on this designation, ViGenCell Inc. plans to prepare for conditional marketing authorization using the results of its clinical trials. Conditional marketing authorization is a type of approval granted on the condition that additional clinical trials or other requirements are conducted after the product is launched. This designation does not in itself guarantee marketing authorization; the actual decision on approval will be determined following the MFDS’s review of the submitted data.
The company also expects the review period to be shortened through the priority review process. According to ViGenCell Inc., while the review period for general product approvals is 120 business days, the priority review process aims to be completed within 90 business days.
VT-EBV-N was designated as an orphan drug in the development stage by the MFDS in 2019. Subsequently, in a Phase 2 clinical trial, it achieved statistical significance by recording a 2-year disease-free survival (DFS) rate of 95.0% as the primary endpoint. Disease-free survival refers to the proportion of patients who survive without disease recurrence or other related events for a specified period.
The trial was conducted using a randomized, double-blind design, and the 2-year disease-free survival rate in the control group was 77.6%. The difference between the treatment group and the control group was 17.4 percentage points.
According to the company, the treatment group’s overall survival (OS) rate remained at 100% even after four years of follow-up. The findings were presented as oral presentations at this year’s American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) conferences.
Preparations are also underway to administer the treatment to patients through the Advanced Regenerative Medicine system. VT-EBV-N received a favorable decision from the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Deliberation Committee last April and, in September, received approval for South Korea’s first Advanced Regenerative Medicine treatment plan from the Ministry of Health and Welfare. Accordingly, ViGenCell Inc. announced that patient administration is scheduled to take place at Yeouido St. Mary’s Hospital of the Catholic University of Korea within this year.
Ki Pyeong-seok, CEO of ViGenCell Inc., stated, “The designation as a fast-track candidate reflects the regulatory authorities’ recognition of the therapeutic value of ‘VT-EBV-N’ and the unmet medical need it addresses.” He added, “We will utilize the expedited review process to prepare for conditional marketing authorization without delay, while also accelerating discussions on global technology transfer.”
Tension is mounting in the domestic credit market following the U.S. Federal Reserve’s decision last September to raise the benchmark interest rate for the first time in three years and two months. As…
#HYUNDAI BIOSCIENCE CO., LTD.’s oral anticancer drug candidate “Penitrium” (CP-PCA07) has obtained approval for use in a specific therapeutic context for the first patient enrolled in a domestic prost…
“Herjumma,” a treatment for breast and stomach cancer. (Active ingredient: trastuzumab) (Photo: Celltrion)
Celltrion(068270)has secured a large-scale supply contract for “Herjumma” (active ingredi…